Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium.
Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, Goodman A, Gottesman MH, Granger CV, Greenberg SJ, Herbert J, Krupp L, Lava NS, Mihai C, Miller AE, Perel A, Smith CR, Snyder DH. Jacobs LD, et al. Among authors: miller ae. Mult Scler. 1999 Oct;5(5):369-76. doi: 10.1177/135245859900500511. Mult Scler. 1999. PMID: 10516782
Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium.
Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, Baier M, Rea DF, Apatoff BR, Blitz KM, Coyle PK, Frontera AT, Goodman AD, Gottesman MH, Herbert J, Holub R, Lava NS, Lenihan M, Lusins J, Mihai C, Miller AE, Perel AB, Snyder DH, Bakshi R, Granger CV, Greenberg SJ, Jubelt B, Krupp L, Munschauer FE, Rubin D, Schwid S, Smiroldo J; New York State Multiple Sclerosis Consortium. Weinstock-Guttman B, et al. Among authors: miller ae. Mult Scler. 2003 Jun;9(3):293-8. doi: 10.1191/1352458503ms909oa. Mult Scler. 2003. PMID: 12814178
Ethical issues in MS clinical trials.
Miller A. Miller A. Mult Scler. 2005 Feb;11(1):97-8. doi: 10.1177/135245850501100119. Mult Scler. 2005. PMID: 15732276 No abstract available.
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment.
Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS. Polman CH, et al. Among authors: miller ae. Neurology. 2008 Mar 25;70(13 Pt 2):1134-40. doi: 10.1212/01.wnl.0000306410.84794.4d. Neurology. 2008. PMID: 18362273
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Goodman AD, Brown TR, Cohen JA, Krupp LB, Schapiro R, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F202 Study Group. Goodman AD, et al. Neurology. 2008 Oct 7;71(15):1134-41. doi: 10.1212/01.wnl.0000326213.89576.0e. Epub 2008 Jul 30. Neurology. 2008. PMID: 18672472 Clinical Trial.
Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW. Rudick RA, et al. Among authors: miller ae. Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212. Mult Scler. 2009. PMID: 19667023
11,275 results
You have reached the last available page of results. Please see the User Guide for more information.